You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Rapid Point-of-Care Diagnostics to Detect Serologic Status of Individuals for Select Viral Infections

    SBC: Zymeron Corporation            Topic: NIAID

    CytomegalovirusCMVis a very common intrauterine infectionaffecting approximately one in everychildrenThe overall disease burden in the US with congenital CMV was estimated at $billion annuallyCMV is also a cause of serious morbidity and fatal infections in immunocompromised patientsThere is currently no generally accepted therapy and developing a CMV vaccine is high priorityCurrently CMV trials re ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. High Throughput CRISPR/Cas9 cell line generation using the CellRaft Array

    SBC: Cell Microsystems, Inc.            Topic: 400

    Project SummaryGenome editing technologies, such as CRISPR/Cas9 provide a rapid, and targeted means of both knocking out gene expression and knocking in gene modifications. Since our initial Phase I submission, the utility of CRISPR technology has expanded beyond the generation of cell lines, to forward genetic screening, in vivo manipulation of gene expression and even human therapeutics. Phase I ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Software for predicting a drug's potential to cause acute kidney injury

    SBC: DILIsym Services, Inc.            Topic: 400

    The goal of this project is to develop novel technology for predicting drug-induced kidney injury such as caused by systemic antimicrobials, diuretics, anticancer agents, and anti-inflammatory drugs. Drugs cause approximately 20 percent of community- and hospital- acquired episodes of acute renal failure, but the incidence in older adults may be as high as 60 percent. A significant problem is that ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: Glycan Therapeutics Corporation            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Low cost retinal optical coherence tomography for point of care use

    SBC: Lumedica, Inc            Topic: NEI

    The objective of this research is to create a clinical prototype of a new optical coherence tomography (OCT) system suitable for diagnostic retinal imaging at the point of care. The target system price will be one third the price of currently available research OCT systems while providing performance comparable to other entry level OCT imaging systems. By breaking the $15,000 system barrier we wil ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A Comprehensive Newborn Screening Solution for Duchenne and Congenital Muscular Dystrophies

    SBC: Baebies, Inc.            Topic: NICHD

    Congenital genetic abnormalities are a leading cause of childhood mortality and morbidity. While routine newborn screening (NBS) has dramatically improved health outcomes, many congenital disorders such as Duchenne muscular dystrophy (DMD) and other congenital muscular dystrophies (CMD) are not currently detected by routine NBS. Presymptomatic identification through NBS is critical to facilitate e ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. ALow Blood Volume Platform for Global Newborn Screening of Common, Treatable Conditions

    SBC: Baebies, Inc.            Topic: NICHD

    An estimated 80% of babies born worldwide (approximately 100 million each year) currently do not receive any newborn screening care. Newborn screening (NBS) is an immensely successful testing program that identifies those at increased risk for common, treatable congenital disorders; the pre-symptomatic identification of these disorders in newborns enables the rapid initiation of treatments and red ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. System for faster microarray assays and end-to-end workflow automation

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACTMicroarrays are an important research tool (genomics and proteomics) and clinical tool (biomarker discovery and diagnosis). Current microarray processing methods are limited by slow assay kinetics, are not amenable to automation, and require high volume of expensive reagents/buffers. Miniaturization of these technologies has been explored to improve throughput. The demand for microarrays c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia

    SBC: Baebies, Inc.            Topic: NICHD

    ABSTRACT Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia (SBIR Phase IIB) Hyperbilirubinemia (jaundice) affects more than half of all newborns and is typically benign if identified and treated promptly. Without proper treatment, high bilirubin leads to serious neurological dysfunction including neuro-motor, auditory, speech, cognition, and language disturbances. Rapid ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government